Imai Atsushi, Ichigo Satoshi, Matsunami Kazutoshi, Takagi Hiroshi, Kawabata Ichiro
Department of Obstetrics and Gynecology, Matsunami General Hospital, Kasamatsu, Gifu 501-6062, Japan.
Mol Clin Oncol. 2017 Jun;6(6):807-810. doi: 10.3892/mco.2017.1237. Epub 2017 May 5.
Improvements in cancer therapy have enabled further insight into the long-term effects of treatment, including the highly prevalent gonadal failure. The focus of treatment has been shifted to the preservation of fertility, which may be achieved by preventing ovarian toxicity. To this end, new molecular-targeted agents, including monoclonal antibodies, have been developed and used in a standard procedure for managing different cancers. However, the prolonged antitumor activity of these drugs may cause the emergence of new toxic effects. The aim of the present review was to discuss the leading toxic effect of the anti-angiogenic agent bevacizumab on ovarian function in female patients of reproductive age, which may be observed and expected during in clinical practice. The majority of bevacizumab-induced side effects are expected to be transient and eliminated within the anticipated drug clearance time frame; however, fundamental investigations on these effects are required for generating more evidence-based practice guidelines.
癌症治疗的进展使人们能够进一步深入了解治疗的长期影响，包括高度普遍的性腺功能衰竭。治疗的重点已转向生育力的保护，这可以通过预防卵巢毒性来实现。为此，包括单克隆抗体在内的新型分子靶向药物已被开发出来，并用于治疗不同癌症的标准程序中。然而，这些药物延长的抗肿瘤活性可能会导致新的毒性作用出现。本综述的目的是讨论抗血管生成药物贝伐单抗对育龄期女性患者卵巢功能的主要毒性作用，这在临床实践中可能会被观察到并有所预期。贝伐单抗引起的大多数副作用预计是短暂的，并会在预期的药物清除时间范围内消除；然而，需要对这些影响进行基础研究，以制定更多基于证据的实践指南。
